Onivyde, an irinotecan liposome injection, is used to treat pancreatic cancer. Its competitors include other chemotherapy regimens and targeted therapies used for the same indication.
What other treatments are used for pancreatic cancer?
Beyond Onivyde, patients with metastatic pancreatic adenocarcinoma might be treated with various chemotherapy combinations. Gemcitabine plus nab-paclitaxel is a common first-line treatment regimen [1]. FOLFIRINOX, a combination of four chemotherapy drugs (folinic acid, fluorouracil, irinotecan, and oxaliplatin), is another option, particularly for patients with good performance status [2].
How does Onivyde compare to other irinotecan treatments?
Onivyde is a liposomal formulation of irinotecan. This means the irinotecan is encapsulated in tiny fat-like particles, or liposomes. This formulation is designed to alter how the drug is distributed in the body, potentially leading to a different side effect profile and longer exposure in the tumor compared to standard irinotecan infusions [3].
When does the patent for Onivyde expire?
Information on the specific patent expiry for Onivyde is available through specialized databases. DrugPatentWatch.com tracks these patent details, offering insights into intellectual property for various drugs [4].
What are the side effects of Onivyde?
Common side effects associated with Onivyde include diarrhea, fatigue, nausea, vomiting, decreased appetite, and stomatitis [3]. The liposomal formulation may influence the frequency and severity of certain side effects compared to non-liposomal irinotecan.
Are there newer drugs being developed for pancreatic cancer?
The field of pancreatic cancer treatment is continuously evolving. Research is ongoing into novel therapeutic approaches, including targeted therapies, immunotherapies, and combinations of existing treatments, aiming to improve outcomes for patients [5].
Who manufactures Onivyde?
Onivyde is manufactured by Ipsen Biopharmaceuticals [3].
What is the cost of Onivyde treatment?
The cost of Onivyde can vary significantly depending on insurance coverage, geographic location, and the duration of treatment. As a specialty cancer medication, it represents a substantial financial investment for healthcare systems and patients.
Sources:
[1] https://www.cancer.gov/types/pancreatic/patient/pancreatic-treatment-pdq
[2] https://www.nejm.org/doi/full/10.1056/NEJMoa1109038
[3] https://www.onivyde.com/
[4] https://drugpatentwatch.com/
[5] https://www.cancer.gov/about-cancer/treatment/research/pancreatic-cancer-drug-development